Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy Life Science Investing
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update Life Science Investing
Medtronic to announce financial results for its first quarter of fiscal year 2025 Life Science Investing
Novartis receives FDA accelerated approval for Fabhalta® , the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy Pharmaceutical Investing
Radiopharm Theranostics: Developing Innovative Radiopharmaceuticals for a Highly Underserved Oncology Sector Geography
Medtronic announces FDA approval of Simplera CGM and global partnership with Abbott Life Science Investing
